VTE Prophylaxis in Cancer – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) prophylaxis in cancer comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of cancer patients eligible for VTE prophylaxis for each country for 13 different types of cancer, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan in this report.
Clarivate Epidemiology’s VTE prophylaxis in cancer forecast will answer the following questions:
- Of all people with breast cancer, bladder cancer, cervical cancer, colorectal cancer, gastric cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, ovarian cancer, pancreatic cancer, prostate cancer, malignant melanoma, non-small-cell lung cancer, or renal cell carcinoma, how many in each of the major markets is eligible for VTE prophylaxis?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of VTE prophylaxis in cancer over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides 20 years of forecast data for the following VTE in cancer patient populations:
- Drug-treatable prevalent cases of VTE prophylaxis in cancer by type of cancer.
Note: Coverage may vary by country and region.
